Skip to main content
Clinical Trials/NCT03559296
NCT03559296CompletedNot Applicable

The Inter- and Intra-rater Reliability of Subcutaneous Echogenicity (SEG) Grade and Subcutaneous Echo-free Space (SEFS) Grade in Postmastectomy Lymphedema

Marmara University1 site in 1 country50 target enrollmentStarted: July 1, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
50
Locations
1
Primary Endpoint
International Society of Lymphology (ISL) stage by rater 1

Study Overview

Brief Summary

The aims of this study is to determine the inter- and intra-rater reliability of SEG and SEFS grade systems for postmastectomy lymphedema.

Detailed Description

The clinical severity of lymphedema in an extremity is generally graded according to the International Society of Lymphology (ISL) stage. Stage 0 which refers to a latent or subclinical condition where swelling is not evident despite impaired lymph transport. It may exist months or years before overt edema occurs (Stages I-III). Stage I represents an early accumulation of fluid relatively high in protein content (e.g., in comparison with "venous" edema) and subsides with limb elevation. Pitting may occur. Stage II signifies that limb elevation alone rarely reduces tissue swelling and pitting is manifest. Late in Stage II, the limb may or may not pit as tissue fibrosis supervenes. Stage III encompasses lymphostatic elephantiasis where pitting is absent and trophic skin changes such as acanthosis, fat deposits, and warty overgrowths develop. Within each Stage, severity based on volume difference can be assessed as minimal (<20% increase) in limb volume, moderate (20-40% increase), or severe (>40% increase).

Because the ISL stage mainly consists of findings achieved by physical examinations and represents the most severely affected arm, it is subjective and may not reflect the distribution and mode of progression of the disease. The characteristic skin and subcutaneous tissue changes in extremities with chronic lymphedema are caused by changes in the extracellular matrix, such as connective tissue hypertrophy, fat accumulation resulting from both fat hypertrophy and an increased number of adipocytes, and interstitial protein-rich fluid accumulation. Ultrasound has been used to assess and diagnose lymphedema related changes. Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema are developed in order to grade lymphedema objectively and to delineate the disease status more clearly. However, the reliability of SEG and SEFS has not been evaluated. The aims of this study is to determine the inter- and intra-rater reliability of SEG and SEFS grade systems for postmastectomy lymphedema. Two physiatrist (one ten-year-experienced and one five-year-experienced in musculoskeletal ultrasonography) independently and alternately will assess the subjects once for each assessment. Three days later after the initial examination, one of the physiatrists reassessed the patients. The inter- and intra-rater reliability will be determined using kappa.

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with unilateral postmastectomy lymphedema

Exclusion Criteria

  • Bilateral lymphedema
  • The patients who had known systemic edemagenic conditions (e.g., cardiac/hepatic/renal failure, terminal cancer, on chemotherapy), and/or with cancer recurrence were excluded

Outcomes

Primary Outcomes

International Society of Lymphology (ISL) stage by rater 1

Time Frame: Day 3

stage of the clinical severity of lymphedema

International Society of Lymphology (ISL) stage by rater 2

Time Frame: Day 0

stage of the clinical severity of lymphedema

Secondary Outcomes

  • elbow joint point affected arm(Day 0)
  • 15 cm above the elbow joint point affected arm(Day 0)
  • 15 cm above the elbow joint point unaffected arm(Day 0)
  • MCP joint level unaffected arm(Day 0)
  • 15 cm below the elbow joint point unaffected arm(Day 0)
  • Affected extremity volume (mL)(Day 0)
  • Unaffected extremity volume (mL)(Day 0)
  • Subcutaneous echo-free space (SEFS) grade by rater 1(Day 3)
  • MCP joint level affected arm(Day 0)
  • wrist joint level affected arm(Day 0)
  • wrist joint level unaffected arm(Day 0)
  • 15 cm below the elbow joint point affected arm(Day 0)
  • elbow joint point unaffected arm(Day 0)
  • Subcutaneous echogenicity (SEG) grade by rater 1(Day 3)
  • Subcutaneous echogenicity (SEG) grade by rater 2(Day 0)
  • Subcutaneous echo-free space (SEFS) grade by rater 2(Day 0)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials